Actively Recruiting
The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques
Led by General Hospital of Shenyang Military Region · Updated on 2026-04-27
100
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Intracranial atherosclerotic disease is the most common cause of ischemic stroke that is directly attributed to the progression or rupture of intracranial high-risk plaque in Asia. Many studies mainly from Euro-American population with a focus on extracranial carotid plaque have fully demonstrated the advantages of intensive statin therapy on stabilizing or reversing plaque burden, reversing plaque composition presenting that lipid-rich necrotic core (LRNC) is gradually replaced by fibrous tissue, and even reversing pattern of arterial remodeling to reduce the occurrence of cerebrovascular events. Yet, direct evidence of the effect of intensive statin therapy on intracranial atherosclerotic plaques is lacking and the effect of statin intensity and duration on intracranial plaque burden and composition is still unclear. High resolution magnetic resonance imaging (HRMRI) is a new and non-invasive technique that enable to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery. Based on above discussion, the investigators conduct this study to further determine the effect of intensive statin in ischemic stroke with intracranial atherosclerotic plaques.
CONDITIONS
Official Title
The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient age between 18-80 years
- Stroke onset within 1 week
- NIHSS score of 12 or less
- Acute ischemic stroke confirmed by head CT or MRI
- Premorbid modified Rankin Scale score of 1 or less
- Less than 50% stenosis in carotid artery, vertebral artery, and intracranial internal carotid artery on lesion side
- Culprit plaque or possible culprit plaque with plaque burden of 40% or more in the proximal middle cerebral artery M1 segment or basilar artery
- Signed informed consent
You will not qualify if you...
- Intracranial hemorrhage found by head CT
- Stroke caused by cardioembolic origin such as atrial fibrillation, valvular heart disease, or aortic arch atherosclerosis
- Severe liver or kidney dysfunction
- Pregnant female
- Abnormal elevation of creatine phosphokinase
- Planned stent angioplasty
- Poorly controlled blood sugar
- Statin use within 1 month before stroke
- Uncontrolled hypertension over 140/90 mmHg after medication
- Unwilling or unable to comply with study visits, lifestyle guidelines, treatment plan, or tests
- Assessed as unsuitable for this clinical study by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
General Hospital of ShenYang Military Region
Shenyang, China
Actively Recruiting
Research Team
X
Xinhong Wang, Doctor
CONTACT
Y
Yu Cui, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here